Quintiles and IMS jump on M&A bandwagon

Merger will create $18bn clinical trials and data specialist

Pfizer weighs split to cut tax bill

Drugmaker says part of business could be relocated overseas

F1HYDP A logo sign outside of a facility occupied by Quintiles Transnational in Overland Park, Kansas on August 23, 2015.

IMS Health/Quintiles: lab experiment

A merger of equals is not always about slashing costs

Witty looks to cement his GSK legacy

Chief must maintain the momentum if he is to leave the drugmaker on a high

Canadian pharma raises NHS eye drug price 14-fold

Concordia strategy triggers fears over price gouging

Shire chief shrugs off investor protests

Drugmaker remains one of the fastest growing in its sector

Mouthwash to be life saver for babies

GSK uses ingredient in Corsodyl to treat umbilical cord infection

Valeant probes revealed in delayed report

Drugmaker staves off default on $30bn and overhauls board

Pfizer And AstraZeneca's Billion Dollar Battle...Boxes containing various pharmaceutical products are seen on display in the pharmacy department of a drugstore in London, U.K., on Friday, May 2, 2014. AstraZeneca Plc rejected Pfizer Inc.'s sweetened takeover proposal, saying the 63.1 billion-pound ($106.5 billion) offer fails to recognize the value of the promising experimental medicines under development by the U.K.'s second-biggest drugmaker. Photographer: Chris Ratcliffe/Bloomberg

AstraZeneca cuts costs for cancer drive

Pharma group moves to specialised lower-volume medicines

Investors rise up in day of protest on pay

Weir, Shire and CRH all feel shareholder wrath

Pharma deals reignite M&A boom

Abbott, AbbVie and Sanofi in separate tie-ups worth $45bn

AbbVie-Stemcentrx move fuels pharma deals

Drugmaker hopes biotech will reduce reliance on blockbuster medicine

Sanofi makes $9.3bn bid for Medivation

French pharmaceuticals group aims to be leader in oncology

Ackman admits fault in Valeant investment

Hedge fund billionaire in mea culpa as drug prices put under pressure

‘White House race not key to drug costs’

GSK chief says US election one of many factors adding to pressure

UBS raises $471m for cancer investment fund

Bank aims to supplement work of charities and public programmes

Sir Andrew Witty fuels GSK turnround hope

New products help offset drugs facing rise of generic competition

Tony Coles – mission against Alzheimer’s

Big-company veteran on fundraising and hiring for biotech start-up

Africa life expectancy jumps dramatically

Longevity gains provide upbeat counterpoint to gloom on continent

Drug prices: Tweaking the formula

UK regulators are under pressure from Big Pharma as well as patients

EDITOR’S CHOICE

Special report

insulin vials ©Jacob Ehrbahn Combating Diabetes

Special report

An elderly man uses a magnifier to see the descriptions on a pack of medicine at a pharmacy in Dandong, Liaoning province March 30, 2011 ©Jacky Chen/Reuter Health: Emerging Markets

COMPANIES NEWS ON TWITTER

More FT Twitter accounts
SHARE THIS QUOTE